TLDR Biotech
All the top biotech and pharma industry updates, straight to your inbox in only one email. Trusted by 1900+ biotech and pharma professionals.
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | March 31 - April 1, 2025
FDA layoffs spark concerns about US drug regulation, AIRNA $155M Series B for RNA editing therapies in rare genetic diseases, Eagle Pharmaceuticals sells Bendeka royalty rights, Eli Lilly's solbinsiran (targeting ANGPTL3) delivers positive Ph2 data in mixed dyslipidemia, Carisma Therapeutics begins company shutdown process + 30 more stories
Biotech & Pharma Updates | March 30 - 31, 2025
Isomorphic Labs (of AlphaFold 3 fame) closes a massive $600M fundraise, AstraZeneca's Imfinzi FDA label expansion into muscle-invasive bladder cancer before and after surgery, Novo Nordisk's pair of positive Ph3 disclosures in cardiovascular diseases, Vertex discontinues development of islet cell therapy drug-device combo for type 1 diabetes, Texas judge overturns FDA's plan to regulate lab-developed tests + 28 more stories
Biotech & Pharma Updates | March 27 - 30, 2025
Ayrmid launches competing offer to buy bluebird bio for $45 million, Novartis' Pluvicto gets an FDA label expansion in prostate cancer, Novo Nordisk in-licenses another obesity asset (this time from Texas-based Lexicon Pharmaceuticals), AbbVie + J&J to provide drug data for OpenFold3 AI model development, CBER's Dr. Peter Marks ousted much to CGT community's dismay + 32 more stories
Biotech & Pharma Updates | March 26 - 27, 2025
Anti-vaccine advocate tapped to lead HHS autism-vaccine study, Soleno Therapeutics' Vykat XR lands FDA approval to treat hyperphagia in patients with Prader-Willi syndrome, Galatea Bio $25M to drive AI-driven genomic research, Chiesi invests €430M ($466M) to redevelop Milan site for inhalers and biologics, Arbutus Biopharma cuts 57% of workforce to focus on imdusiran whilst halting all other research + 28 more stories
Biotech & Pharma Updates | March 25 - 26, 2025
Bayer in-licenses PRMT5 inhibitor from China's Puhe BioPharma, FDA expands Exelixis' cabozantinib (tyrosine kinase inhibitor) label for neuroendocrine tumors in adults and children 12+, Epicrispr Biotechnologies $68M Series B to fuel epigenetic editing therapy for rare muscle disease, CGT CDMO and service provider ElevateBio cuts 17% of staff + 27 more stories
Biotech & Pharma Updates | March 24 - 25, 2025
Drug formulation biotech Lyndra Therapeutics shutters, Merck & Co. pays $200M to in-license Jiangsu Hengrui's experimental LpA-blocking heart drug, Hillstar Bio launches with $67M and big autoimmune dreams, DOGE reverses closure of three FDA sites including St. Louis drug quality lab, NIH ends future funding for studies on health effects of climate change + 32 more stories
Biotech & Pharma Updates | March 23 - 24, 2025
23andMe declares bankruptcy, Novo Nordisk in-licenses "triple-G" obesity med from a Chinese biotech, Tempero Bio's $70M Series B to develop substance use disorder therapies, PolTREG + Antion Biosciences partner to develop allogeneic off-the-shelf CAR-Treg therapies, Opthea future indout as their wet AMD hopeful sozinibercept flops in Ph3 + more stories
Biotech & Pharma Updates | March 20 - 23, 2025
J&J pledges massive $55B US domestic manufacturing push, a16z plans a (downsized) $750M Bio Fund, AstraZeneca pledges $2.5B infrastructure investment in Beijing, HHS' healthcare quality research agency could face 80-90% staff cuts + 27 more stories
Biotech & Pharma Updates | March 19 - 20, 2025
Sanofi to pay up to $1.9B for Dren Bio's bispecific for autoimmune diseases, Alnylam's Amvuttra approved by FDA for transthyretin amyloidosis with cardiomyopathy, Delpharm receives $42M from Canada to upgrade former Sandoz plant in Quebec that produces essential sterile injectables, Century Therapeutics pivots cell therapy aspirations to autoimmune diseases after cancer failure, medical orgs and doctors jointly affirm vaccine safety amid misinformation and infectious disease outbreaks + 35 more stories
Biotech & Pharma Updates | March 18 - 19, 2025
Roche's up to $1B cancer drug target partnership with Oxford BioTherapeutics, REGENXBIO's DMD gene therapy delivers promising (and safe) Ph1/2 data, Ampersand Biosciences $65M Series B to fuel “smart medicines” ambitions in immuno-inflammation and immuno-oncology, CARGO Therapeutics shutters R&D and lays off 90% of staff, Trump admin considering major cuts to CDC's HIV prevention division + 23 more stories
Biotech & Pharma Updates | March 17 - 18, 2025
Sofinnova Partners grabs attention by launching three separate NewCos AND announcing their €165M ($180M) Biovelocita II fund, Arbor raises a $74M Series C to advance their ABO-101 gene editing therapy, Sarepta stock sinks after a DMD patient dies from Elevidys-induced acute liver failure + 29 more stories
Biotech & Pharma Updates | March 16 - 17, 2025
AstraZeneca bets big on cell therapies potential in-vivo future by snapping up EsoBiotec for up to $1B, Pillar VC raises $175M Fund IV, Curevo $110M Series B to support shingles vaccine development, Incyte's JAK1 inhibitor povorcitinib meet Ph3 goals but disappoints investors, NIH cancels 30-year diabetes study funding amid Trump admin's actions against Columbia University + 38 more stories